anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Persons with chronic kidney disease (CKD) are at increased risk of adverse events, early mortality and multimorbidity. A detailed overview of adverse event types and rates from a large CKD cohort under regular nephrological care is missing. We generated an interactive tool to enable exploration of adverse events and their combinations in the prospective, observational German CKD (GCKD) study.
METHODS: The GCKD study enrolled 5217 participants under regular nephrological care with an estimated glomerular filtration rate of 30-60 or >60 mL/min/1.73 m2 and an overt proteinuria. Cardiovascular, cerebrovascular and peripheral vascular, kidney, infection, and cancer events, as well as deaths were adjudicated following a standard operation procedure. We summarized these time-to-event data points for exploration in interactive graphs within an R shiny app. Multivariable adjusted Cox models for time to first event were fitted. Cumulative incidence functions, Kaplan-Meier curves and intersection plots were used to display main adverse events and their combinations by sex and CKD etiology.
RESULTS: Over a median of 6.5 years, 10 271 events occurred in 2947 participants (56.5%), of which 680 participants (13.0%) died. The new publicly available interactive platform enables readers to scrutinize adverse events and their combinations as well as mortality trends as a gateway to better understand multimorbidity in CKD: incident rates per 1000 patient-years varied by event type, CKD etiology and baseline characteristics. Incidence rates for the most frequent events and their recurrence were 113.6 (cardiovascular), 75.0 (kidney) and 66.0 (infection). Participants with presumed diabetic kidney disease and men were more prone to experiencing events.
CONCLUSION: This comprehensive explorative tool to visualize adverse events (https://www.gckd.org/studienhintergrund/previous-study-results/event-analysis/), their combination, mortality and multimorbidity among persons with CKD may serve as a valuable resourec for patient care, identification of high-risk groups, health services and public health policy planning.
The invention discloses a composition for improving resistance of an organism to exogenous pathogenic factors and a preparing method thereof. The composition is prepared from suberect spatholobus stems, radix smilax riparia, scarlet kadsura roots, rhizoma cyperi, radix achyranthis bidentatae, radix cudramiae, the root of three-nerved spicebush, hyptis suaveolens, sheepear inula herbs and herba hypericum japonicum. Animal pharmacodynamics results show that in an experiment of adjusting the immune function of mice, absorbancy difference between splenocyte culture fluid into which Con A is added and splenocyte culture fluid into which Con A is not added can be remarkably increased, and thymus gland and spleen indexes of the mice are increased. It is hinted that thymus gland and spleen development is promoted by the composition to promote differentiation of T lymphocytes and generation of B lymphocytes. The resistance of an embodiment group is obviously superior to that of a model group. It can be considered that the composition can promote differentiation of T lymphocytes and generation of B lymphocytes, and therefore the immunologic function of the mice is improved.
PURPOSE:To obtain a make-up cosmetic having excellent dispersibility of pigment and excellent applicability, spreadability, gloss and adhesivity, by adding skim milk, defatted milk or reduced milk as an additive. CONSTITUTION:The objective make-up cosmetic contains 3.0-10.0wt.% of skim milk, defatted milk or reduced milk in terms of solid component. Since the pH of an aqueous solution of skim milk is 6.54 and the solution in maintained in weakly acidic state, the milk is an ideal compounding component from the viewpoint of dermatic physiology. The above cosmetic can be produced by mixing the raw materials and subjecting the mixture to heating, stirring, kneading with a roller, etc. When skim milk is used as the additive, the contained fat spheres are further divided into finer particles during the stirring and kneading operations to cover the surface of pigment, improve the affinity of the pigment with other raw materials, increase the moisture-retention, improve the color and gloss and give a product having excellent feeling to the skin. In the case of using defatted milk or reduced milk, the water is evaporated by heating to enable uniform mixing of the components.
Hydroxyurea causes severe myelosuppression. Treatment with HYDREA should not be initiated if bone marrow function is markedly depressed. Bone marrow suppression may occur, and leukopenia is generally its first and most common manifestation. Thrombocytopenia and anemia occur less often and are seldom seen without a preceding leukopenia. Bone marrow depression is more likely in patients who have previously received radiotherapy or cytotoxic cancer chemotherapeutic agents; use HYDREA cautiously in such patients.

Evaluate hematologic status prior to and during treatment with HYDREA. Provide supportive care and modify dose or discontinue HYDREA as needed. Recovery from myelosuppression is usually rapid when therapy is interrupted.
The invention is in the field of caries prevention and treatment, in particular minimally-invasive, or non-invasive dental decay treatment. It relates to a composition and a kit comprising a self-assembling peptide, such as the self-assembling peptide P11-4 or P11-8, and a dental agent, namely a dental sealant, e.g. a glass-ionomer cement-based sealant or a resin-based sealant, a fluoride varnish, a dental restorative material or a bonding agent. The invention further relates to a composition and kit comprising a self-assembling peptide and a dental agent for use in the treatment of a carious lesion, preferably a cavitated carious lesion. The self-assembling peptide prevents secondary caries after failure of the dental agent used in treatment of cavitated caries, especially in case of a failing interface between the restoration with the dental agent and the tooth. The composition and kit of the present invention may also be used for pulp capping.
INTRODUCTION: Iliac aneurysms occur in 10% of patients with abdominal aortic aneurysms (AAA). There are three different endovascular approaches to their treatment in the context of infrarenal Endovascular Aortic Aneurysm Repair (EVAR): occlusion by coiling the internal iliac, incorporation using an iliac branch device, and delaying repair using a bell bottom limb. We sought to determine outcomes associated with these three strategies in our practice.
METHODOLOGY: The study was a combined prospective cohort study with a retrospective arm: prospective patient recruitment was done for 1 year from September 2019 and ended by September 2020, and retrospective data was collected from 2017 to 2019. Demographic, procedural, and imaging data was collected. SPSS was used to analyze data as patients were classified by limbs in four groups: iliac branched, bell bottom, coil and cover technique, and standard treated limbs.
RESULTS: There were 65 male and 4 female patients included in this study incorporating 137 limbs with a mean age of 78 years (SD ± 8 years). Two patients died after discharge (at 3 and 21 months postoperatively, without hospital admission) and five patients were lost to long-term follow-up. Three patients had operations that deviated from the plan: one was an IBD converted to bell bottom, one was an IBD that was converted to coil and cover, and one was a bell bottom that did not seal. Follow-up revealed late type IB endoleak in three bell bottom limbs and one limb treated with coil and cover. Common iliac occlusion occurred in one IBD, three bell bottom limbs, and two limbs treated with coil/cover technique. There were four additional ischemic events (buttock claudication in three and intestinal ischemia in one): all ischemic events occurred in the coil and cover group (p = .001).
CONCLUSIONS: Given the small population size examined in this study, there is no statistical difference between treatment groups; however, there was a trend toward bell bottom technique being associated with higher incidence of type IB endoleak. Coil and cover technique was associated with decreased IB endoleak; however, Buttock claudication and intestinal ischemia occurred more significantly in this group. Using IBD may be the best strategy to improve short- and long-term outcomes in patients with iliac aneurysms.
Thorax and total body imaging for quantification of normal biodistribution and myocardial sympathetic innervation. PET imaging to 210 minutes post-administration.
The present invention relates to a anti-cancer slow-release preparation containing glucocorticoid and chemotherapeutic medicine. Said anti-cancer slow-release preparation is a slow-release injection formed from slow-release microsphere and solvent. The slow-release microsphere includes anti-cancer effective component and slow-release auxiliary material, its solvent is a special solvent containing suopension adjuvant. The glucocorticoid is selected from prednisolone, methyl prednisolone, dexamethasone, betamethasone, triamcinolone and triamcinolone acetonide, its chemotherapeutic medicine is selected from phosphoinositide 3-kinase inhibitor and pyrimidine analogues. The slow-release auxiliary material is polylactic acid and its copolymer, polyethylene glycol, carboxyl-terminated polylactic acid copolymer, difatty acid and sebacic acid copolymer, poly (erucidic acid dimer-sebacic acid) and poly (fumaric acid-sebacic acid) biological compatibility macromolecule, and the suspension adjuvant is selected from carboxymethylcellulose sodium, etc. Said invention also can be made into slow-release implantation preparation.
Disclosed is an application of tranilast in the preparation of a drug treating scleredema diabeticorum. Tranilast has been used for many years in the clinical treatment of allergic diseases and keloids, and is a safe and effective drug with few adverse reactions. Now, tranilast is used for scleredema diabeticorum patients who have no clear clinical treatment program. After tranilast has been applied for three months, clinical observations show that symptoms are significantly eased, and B-scans detect that skin thickness is significantly thinner, without any significant adverse reactions. This indicates that the drug rapidly controls skin damage in scleredema diabeticorum patients, and reduces clinical symptoms of scleredema diabeticorum. Tolerance is good, patient compliance is high, adverse reactions are rare, and the clinical efficacy and safety of the drug are good.
<P>PROBLEM TO BE SOLVED: To provide a method for producing capsaicine glycosides ensuring food safety in the production process and to provide a safe use form of the capsaicine.  <P>SOLUTION: The method biochemically produces the glycosides of capsaicines. The capsaicines comprises for example, capsaicine, 8-nordihydrocapsaicine. The capsaicine is subjected to a glycoside formation to produce capsaicine-beta- D-glycopyranoside by using a cultured cell of a vegetable stem such as Pytolacca Americana. The 8-nordihydrocapsaicine is subjected to the glycoside formation for forming 8-nordihydrocapsaicine-beta-D-glycopyranoside by the cultured cell of the vegetable. The capsaicines such as the capsaicine, the 8- nordihydrocapsaicine, are subjected to the glycoside formation by using an enzyme such as CGTase.  <P>COPYRIGHT: (C)2004,JPO
Cystic fibrosis (CF) is a genetic disease caused by variants in the gene encoding for the CF transmembrane conductance regulator (CFTR) protein, a chloride and bicarbonate channel. CFTR dysfunction results in a multiorgan disease with the main clinical features being exocrine pancreatic insufficiency and diffuse bronchiectasis with chronic airway infection leading to respiratory failure and premature death. Over the past decades, major progress has been made by implementing multidisciplinary care, including nutritional support, airway clearance techniques and antibiotics in specialised CF centres. The past decade has further seen the progressive development of oral medications, called CFTR modulators, for which around 80% of people with CF are genetically eligible in Europe. CFTR modulators partially restore ion transport and lead to a rapid and major improvement in clinical manifestations and lung function, presumably resulting in longer survival. CFTR modulators have been game-changing in the care of people with CF. However, many questions remain unanswered, such as the long-term effects of CFTR modulators, especially when treatment is started very early in life, or the new CF-related disease emerging due to CFTR modulators. Moreover, severe complications of CF, such as diabetes or cirrhosis, are not reversed on CFTR modulators and around 20% of people with CF bear CFTR variants leading to a CFTR protein that is unresponsive to CFTR modulators. Challenges also arise in adapting CF care to a changing disease. In this review article, we highlight the new questions and challenges emerging from this revolution in CF care.
Progress in understanding nervous system-cancer interconnections has emphasized the functional role of semaphorins (SEMAs) and their receptors, neuropilins (NRPs) and plexins (PLXNs), in cancer progression. SEMAs are a conserved and extensive family of broadly expressed soluble and membrane-associated proteins that were first described as regulators of axon guidance and neural and vascular development. However, recent advances have shown that they can have a dual role in cancer progression, acting either as tumor promoters or suppressors. SEMAs effects result from their interaction with specific co-receptors/receptors NRPs/PLXNs, that have also been described to play a role in cancer progression. They can influence both cancer cells and tumor microenvironment components modulating various aspects of tumorigenesis such as oncogenesis, tumor growth, invasion and metastatic spread or treatment resistance. In this review we focus on the role of these axon guidance signals and their receptors and co-receptors in various aspects of cancer. Furthermore, we also highlight their potential application as novel approaches for cancer treatment in the future.
The resin salve may be spread directly onto the diabetic ulcer, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the ulcer area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of ulcer secretion.
The dosage of SENSORCAINE / SENSORCAINE WITH EPINEPHRINE administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. Administer the smallest dosage and concentration required to produce the desired result. 

The types of block and recommended SENSORCAINE / SENSORCAINE WITH EPINEPHRINE concentrations are shown in Table 1

At recommended dosages, SENSORCAINE / SENSORCAINE WITH EPINEPHRINE produces complete sensory block, but the effect on motor function differs among the three concentrations. Table 2 provides information on the expected effect on motor function for the three concentrations. 

The duration of anesthesia with SENSORCAINE / SENSORCAINE WITH EPINEPHRINE is such that for most indications, a single dose is sufficient. 

The maximum dosage limit within the recommended dosage range must be individualized in each case after evaluating the size and physical status of the patient, as well as the anticipated rate of systemic absorption from a particular injection site. 

The dosages in Table 3 are recommended as a guide for use in the average adult. These doses may be repeated once every three hours. Do not exceed a total daily dosage of 400 mg in 24 hours. The duration of anesthetic effect may be prolonged by the addition of epinephrine.
Since 2010, A PCA service team in the investigators' hospital have collected multidisciplinary clinical data from all the patients who used IV-PCA postoperatively in aim of the assessment of clinical outcome. The investigators reviewed the collected data from the patients who had used IV-PCA for pain control after an elective surgery under general or spinal anesthesia between Sep. 2010 and March. 2014. The need for informed consent was waived for this study. The investigators have used a disposable PCA pump (Ambix Anaplus®; E-Wha Fresenius Kabi, Korea or accufuser plus®; Woo Young Medical, Korea) and fentanyl was diluted in 100mL with saline for 48 hrs PCA infusion. The pump was set as follows: infusion rate as 2 ml/hr, bolus dose as 0.5 ml or 1 ml, lockout time as 15 min. It was decided at the anesthesiologist's option whether the additional analgesic drug (ketorolac or nefopam) and the antiemetic drug (ondansetron, ramosetron or palonosetron) would be added in PCA or not. The anesthesiologist who performed the anesthesia decided the amount of chosen drugs. Exclusion criteria were as following: age \< 20 years old, age 40 to 69, postoperative ventilator support or intensive care, and imperfect data. The data of the PCA regimen which has been decided were recorded and analyzed. Demographic variables including age, sex, body mass index, American Society of Anesthesiologists (ASA) physical status and history of smoking, motion sickness, postoperative nausea/vomiting, hypertension and diabetes mellitus have been analyzed. Anesthesia and surgery-related variables including the duration of anesthesia, the type of anesthesia (general or spinal), laparoscopy and the operation site (categorized in abdominal, thoracic, upper \& lower extremities, head \& neck, spine and others) were also been analyzed. PCA-related variables included total dose of fentanyl for two days (µg/kg), use of mixed additional analgesics and antiemetics in PCA and discontinuation of PCA. When the patient requested the discontinuation of IV-PCA, the reason and the time have been recorded. Postoperative variables including the numeric rating scale (NRS, 0-10, 0 = no symptom; 10= unthinkable worst pain) for pain, requirements of rescue analgesics and antiemetics were analyzed. And the postoperative complications including nausea, vomiting, headache, dizziness, and sedation were analyzed. All the postoperative variables were recorded at postoperative 0-6 hrs including stay at post-anesthesia care unit, 6-12, 12-18, 18-24 and 24-48 hrs.
Coronavirus disease 2019 (COVID-19) emerged in late 2019 and spread rapidly, resulting in a global pandemic.SARS-CoV-2 encodes nonstructural and structural proteins required for its viral life cycle. Among them, the spike glycoprotein plays a pivotal role in SARS-CoV-2 infection by recognizing and attaching to ACE2 transmembrane protein on host cells. Kintor protocol has been designed to evaluate efficacy and safety of GT0918 in hospitalized subjects with COVID-19 illness. The target population of this study are hospitalized subjects with COVID-19 illness with positive SARS-CoV-2 virus test within 72 hours of randomization. The study will evaluate anti-androgen therapy may effectively prevent progression to the more severe form of COVID-19 illness and death, shorten the time to sustained recovery and decrease the mortality rate. Subject will receive either GT0918 plus standard of care or matched placebo plus standard of care. GT0918/placebo will be given 300mg orally once a day around 30 minutes after meal for 7 days and can be extended up to 14 days per investigator discretion
Subject will have Veraflo™ Cleanse Choice Complete™ dressing applied and used per instructions for use. 3D imaging and wound / peri-wound skin characteristics will be taken during the treatment.
The invention discloses a traditional Chinese medicine composition used for treating hernia. The traditional Chinese medicine composition is prepared from, by weight, 7 to 13 parts of Longan seed, 12 to 17 parts of Atalantia buxifolia (Poir.) Oliv., 5 to 10 parts of actinidia polygama fruit, 7 to 12 parts of Radix Kansui, 9 to 13 parts of Root of Yunna cowparsnip, 11 to 15 parts of semen canavaliae, 10 to 17 parts of peruvian groundcherry herb, 7 to 13 parts of shoot of Omei Mountain Bamboo, 9 to 16 parts of Herb of Twelvestamen Melastoma, 13 to 18 parts of radix saposhnikoviae, 10 to 17 parts of Fortunella hindsii (champ.) Swingle, 8 to 15 parts of Citrus chachiensis Hort., 12 to 17 parts of Angelica citriodora Hance., 16 to 22 parts of Quercus fabri Hance fruit with insect gall, 13 to 18 parts of Micromeria biflora Benth., 6 to 10 parts of lignum dalbergiae odoriferae, and 9 to 17 parts of stem and leaf of rauvolfia verticillate. The traditional Chinese medicine composition is prepared from natural traditional Chinese medicine raw materials based on prescription medication principles of traditional Chinese medicine; it is confirmed by clinical application that curative effect is excellent and reliable, drug properties are mild, no toxic or side effect is caused, and application prospect is promising. The traditional Chinese medicine composition is prepared based on traditional Chinese and western medicine basic theories, and is convenient to prepare; less pain is caused in treatment; and daily work is not influenced.
Patients receive etoposide PO QD on days 1-5 and selinexor PO on days 1, 3, 8, 10, 15, and 17. Treatment may repeat every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving response after 4 courses discontinue treatment; patients achieving response may receive up to 4 courses of maintenance therapy every 8 weeks. Patients may then continue selinexor as monotherapy at the discretion of the principal investigator.
Second line Eribulin 1.23 mg/m2 i.v. on day 1, 8 every 21 days followed by third line Capecitabine 1250 mg/m2 orally twice per day on days 1 to 14 every 21 days.
In patients with chronic HIV infection, HIV replication and abnormalities in immune function persist following treatment with highly active antiretroviral therapy (HAART). Specifically, costimulatory T cell interactions are impaired. The immune modulatory drug thalidomide was recently found to costimulate T cells. Pharmacologic T cell costimulation may compensate for the T cell deficiencies in people with HIV disease and improve immune function. This study will test whether thalidomide treatment enhances HIV and cytomegalovirus (CMV)-specific immunity in patients with HIV and CMV, and will evaluate the effect of thalidomide on HIV replication.

In this study, 40 HIV and CMV infected patients on HAART and 40 HIV uninfected CMV seropositive controls will be randomly assigned to low dose thalidomide or placebo treatment for 28 days. T cell responses and HIV replication and genetic diversification will be assessed.
A method for discovering billable health plan enrollment for a patient includes receiving patient information for one or more patients from a medical service provider. The patient information is analyzed, and a sample of patients and a sample of health care plans are selected based on the analysis. An enrollment eligibility inquiry is sent to each of the health care plans for each of the patients. Each of the health care plans returns an eligibility response that indicates whether any of the patients are enrolled in any of the health care plans for each inquiry. These results are provided to the medical care provider. In addition, these results, along with any feedback from the medical service provider regarding any claims submitted to the health care plans for the enrolled patients, and used to refine the analysis of the patient information for subsequent health care enrollment searches.